Home  /   Products  /   Urological drugs  /   Fosfomycin-LekT intravenous 3 g – [1 sachet]

Fosfomycin-LekT intravenous 3 g – [1 sachet]


Fosfomycin-LekT powder is a broad spectrum antibacterial agent used for acute bacterial cystitis, bacterial nonspecific urethritis.

SKU: 63194 Category:


Phosphomycin-LekT Pharmacodynamics
Fosfomycin [mono (2-ammonium-2-hydroxymethyl-1,3-propanediol) (2R-cis)-(3-methyloxyranil) phosphonate] is a broad spectrum antibacterial agent, a phosphonic acid derivative designed to treat urinary tract infections.
The mechanism of action is associated with inhibition of the first stage of bacterial cell wall synthesis. As a structural analogue of phosphoenolpyruvate, it competitively inhibits irreversibly the enzyme UDF-N-acetylglucosamienolpyruviltransferase, which catalyzes the reaction of UDF-M-acetyl-3-O-(1-carboxyvinyl)-D-glucosamine formation from phosphoenolpyruvate and UDF-N-acetyl-D-glucosamine.
Fosfomycin is also capable of reducing bacterial adhesion to bladder mucosa, which may play a predisposing factor for recurrent infections. The mechanism of action of fosfomycin explains the absence of cross-resistance with other antibiotics and the mutual potency with antibiotics of other classes, such as beta-lactam antibiotics.
Fosfomycin is active against a wide range of Gram-positive and Gram- susceptible microorganisms commonly isolated in urinary tract infections, such as Escherichia coli, Citrobacter spp., Klebsiella spp., Proteus spp., Serratia spp., Pseudomonas aeruginosa, Enterococcus faecalis. The emergence of resistance under laboratory conditions is explained by mutation of gIpT and uhp genes, which control L-alpha-glycerophosphate and glucose phosphate transport, respectively.


Infectious-inflammatory diseases caused by fosfomycin-sensitive microorganisms:
– Acute bacterial cystitis, acute attacks of recurrent bacterial cystitis;
– Bacterial nonspecific urethritis;
– Asymptomatic massive bacteriuria in pregnant women;
– Postoperative urinary tract infections. Prophylaxis against infection during urinary tract surgery and transurethral diagnostic investigations.


– Hypersensitivity to Fosfomycin-LekT and other drug components;
– Severe renal insufficiency (creatinine clearance < 10 ml/min);
– Children under 12 years of age;
– hemodialysis;
– Sucrose/isomaltase deficiency, fructose intolerance, glucose-galactose malabsorption.
Use during pregnancy and lactation
During pregnancy, use only if the expected benefit to the mother outweighs the potential risk to the fetus. Fosfomycin penetrates into the breast milk at very low concentrations.
If Fosfomycin-LekT powder is administered during lactation, breastfeeding should be stopped for the duration of therapy.


Dosage and administration administration
  • Oral administration.
  • Fosfomycin-LekT powder is dissolved in 1/2 cup of water (50-75 ml) or other fluid, stirred until completely dissolved.
  • Fosfomycin-LekT powder is taken once a day on an empty stomach 1 hour before or 2-3 hours after a meal, preferably before bedtime, after bladder emptying.
  • Adults and children 12 to 18 years of age:
  • 1 sachet (3 g) once a day.
  • For prevention of urinary tract infection during surgical and transurethral diagnostic procedures, fosfomycin 3 g is taken 2 times: 3 hours before and 24 hours after the intervention.
  • In more severe cases (elderly patients, recurrent infections), one more sachet is taken 24 hours later.
  • Special patient groups
  • Patients with renal disease
  • In patients with mild to moderate renal insufficiency, no dose adjustment is required. The drug is contraindicated in patients with severe renal insufficiency or in patients undergoing hemodialysis.
  • Patients with liver disease
  • No dosage adjustment is required in patients with hepatic impairment.